Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects With Chronic Hepatitis C Previously Treated With an NS5A Inhibitor + Sofosbuvir Therapy

NCT03092375 is registered in ClinicalTrials.gov with University of Florida as lead sponsor.

NCT NCT03092375
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03092375 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects With Chronic Hepatitis C Previously Treated With an NS5A Inhibitor + Sofosbuvir Therapy
Lead sponsor
University of Florida
Phase
Phase 3
Overall status
Completed
Start date
April 20, 2017
Completion date
February 6, 2020
Enrollment
177 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

hcv, hepatitis c